Chapter 12 244 37. Woodcock J. Expanded Access in modern healthcare, by Janet Woodcock, MD (FDA) at Ax-S Pharma event. Published 2020. Accessed April 3, 2022. https://www.youtube.com/ watch?v=Su60ctaIKpo 38. Bunnik EM, Aarts N. The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians’ Views and Experiences in The Netherlands. J Bioethical Inq. 2021;18(2):319-334. doi:10.1007/s11673-02110090-7 39. Bunnik EM, Aarts N, van de Vathorst S. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs. Health Policy Amst Neth. 2018;122(9):977-983. doi:10.1016/j. healthpol.2018.06.005 40. Polak TB, van Rosmalen J, Uyl – De Groot CA. Response to Open Peer Commentary “Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs.” Am J Bioeth. 2020;20(11):W4-W5. doi :10.1080/15265161.2020.1820113 41. Rozenberg O, Greenbaum D. Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs. Am J Bioeth. 2020;20(7):89-92. doi:10.1080/152651 61.2020.1779857 42. Kearns L, Chapman CR, Moch KI, et al. Gene therapy companies have an ethical obligation to develop expanded access policies. Mol Ther. 2021;29(4):1367-1369. doi:10.1016/j. ymthe.2021.03.008 43. Federal Agency for Medicines and Health. FAQ - Unmet Medical Need V1.5.; 2019. 44. Steger GG, Bartsch R, Wenzel C, et al. Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer. 2005;41(17):26552661. 45. Schubert L, Fisecker L, Thalhammer F, Burgmann H, Steininger C. Letermovir for the compassionate therapeutic use of cytomegalovirus infection. Eur J Clin Microbiol Infect Dis. 2021;40(2):435-439. 46. Lyckegaard E,Håkansson K,Bengtsson B.Budesonide in Crohn’s disease: findings of a compassionate-use program. Hepatogastroenterology. 2007;54(79):20242027. 47. Winqvist M, Andersson PO, Asklid A, et al. Longterm real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematologica. 2019;104(5):e208-e210. 48. Bracarda S, Rottey S, Bahl A, et al. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis. Future Oncol. 2015;11(21):2893-2903. 49. Servais L, Straathof CSM, Schara U, et al. Longterm data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2020;30(1):5-16. 50. Freedman O, Amir E, Dranitsaris G, et al. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Res Treat. 2009;118(2):377-383. 51. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146(2):164-170. 52. Federal Agency for Medicines and Health. Rétributions & Contributions AFMPS – UNMET MEDICAL NEED.; 2022. 53. European Parlement. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC.; 2014. 54. Yang B, Fulcher JA, Ahn J, et al. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab. Clin Infect Dis. 2021;73(11):e4082-e4089. 55. Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19. JAMA. 2021;325(12):1185. doi:10.1001/jama.2021.2747
RkJQdWJsaXNoZXIy MTk4NDMw